{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-043009","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2023-11-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.161524+00:00","generated_at":"2026-06-07T20:21:11.268157+00:00","sec_items":["1.01","2.03","3.02","7.01","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Ensysce completes $1.7M convertible note financing; second closing of $1.133M","bullets":["Total gross proceeds of $1.7M from senior secured convertible notes and warrants; second closing on Nov 28/29, 2023 added $1.133M (net).","Notes convertible at $1.5675/share, 6% interest, 6-month term; monthly redemption begins 90 days after issuance.","Warrants to purchase up to 3.77M shares at $1.5675, exercisable for five years from issuance.","Proceeds to fund PF614 time of onset study and regulatory milestones.","Notes secured by all company assets and guaranteed by subsidiaries EBI OpCo and EBI."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-043009","json":"https://secwatch.observer/filing/0001493152-23-043009.json","markdown":"https://secwatch.observer/filing/0001493152-23-043009.md","text":"https://secwatch.observer/filing/0001493152-23-043009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315223043009/0001493152-23-043009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315223043009/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T20:21:11.268157+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b642b284544f18225aac08ad56b61d905d145a5f","claim":"Ensysce Biosciences, Inc. incurred convertible notes of aggregate principal amount of $1,224,000 with the investors at 6.0% per annum maturing six months from their respective date of issuance.","evidence_excerpt":"the Company issued to the investors referenced above, (i) Notes in the aggregate principal amount of $1,224,000 for an aggregate purchase price of $1,133,333","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315223043009/0001493152-23-043009-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"aggregate principal amount of $1,224,000"},{"label":"Counterparty","value":"the investors"},{"label":"Rate","value":"6.0% per annum"},{"label":"Maturity","value":"six months from their respective date of issuance"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"64f449957ea6efc84ae1f1ce22861391e536747e","claim":"Ensysce Biosciences, Inc. entered into Securities Purchase Agreement with investors valued at $1.7 million (effective 2023-10-23).","evidence_excerpt":"on October 23, 2023, Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) entered into a Securities Purchase Agreement (the “SPA”) for an aggregate financing of $1.7 million with investors.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315223043009/0001493152-23-043009-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"investors"},{"label":"Value","value":"$1.7 million"},{"label":"Effective","value":"2023-10-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}